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SYNOPSIS 
The addition of prophylactic central neck dissection at the time of total thyroidectomy in clinically-
nodal negative papillary thyroid carcinoma was not cost saving in the medium to long term because 
of the initial higher cost and relatively small reduction in recurrence and need for reoperation. 
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ABSTRACT 
Background: Total thyroidectomy (TT) with prophylactic central neck dissection (pCND) remains 
controversial for clinically-nodal negative (cN0) papillary thyroid carcinoma (PTC) and the issue of 
cost has rarely been examined. We aimed to evaluate whether pCND at the time of TT is more cost-
saving than TT alone in the medium to long-term. 
Methods: For a hypothetical group of 50 years old females with a 1.5cm cN0 PTC, a decision-tree 
model using TreeAge Software was developed to simulate outcomes and compare the 20-year 
accumulative direct cost between TT alone and TT+pCND strategies. Baseline values and ranges 
were determined from a systematic review of the literature. Sensitivity analyses were conducted to 
test model strength. Cost estimate of surgical procedures, complications and radioiodine (RAI) 
ablation was based on government gazette. 
Results: The cost accrued per patient in the primary operation under TT alone and TT+pCND 
strategies were USD 6702.81 and USD 10062.35, respectively while the cost in the reoperative 
procedure were USD 12981.40 and USD 12509.09, respectively. The 20-year accumulative cost for 
TT alone and TT+pCND strategies were USD 19888.36 and USD 22760.86, respectively. The 
incremental cost per patient was USD 2872.50. In the univariate and bivariate sensitivity analyses, 
no change in conclusion was seen by varying the rates of complications, annualized locoregional 
recurrences and RAI or by extending the model to 50 years.   
Conclusions 
From a pure economic institution’s perspective, TT+pCND is more expensive in the medium and 
long terms and seems less justified over TT alone in cN0 PTC. 
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INTRODUCTION 
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma with its 
incidence doubled over the last two decades.[1-5] However, despite good prognosis, locoregional 
recurrence (LRR) is common after curative surgery.[6] With recognition of the step-wise 
progression of metastasis from central (level VI) to lateral compartments (levels II-V), routine 
prophylactic central neck dissection (pCND) has been advocated at the time of total thyroidectomy 
(TT) to reduce LRR.[7-9] Although formal central neck dissection is indicated in clinically positive 
nodal disease, it remains controversial in clinically negative nodal disease (cN0).[10] There is little 
evidence to suggest patients with cN0 PTC would benefit from pCND at the time of TT, although a 
recently meta-analysis has found a 35% reduction in LRR over TT alone.[11] However, this was at 
the expense of higher risks of temporary hypoparathyroidism and overall morbidity.[11] Therefore, 
performing pCND may cause initial higher patient morbidity but may be beneficial in the medium 
to long-term because of reduced LRR.[9,11]  
Despite this ongoing debate on whether routine pCND should or should not be performed, the issue 
of cost has rarely been discussed and examined. In the era of cost containment and rising healthcare 
costs, it is imperative that clinicians include dollar cost of a surgical intervention (such as pCND) as 
part of their decision making process. In the context of pCND for cN0 PTC, the question is whether 
the higher expected initial cost (due to greater extent of surgery, higher morbidity and more 
frequent radioiodine (RAI) use) could be compensated in the medium to long term by the lower cost 
from reduced LRR and need for reoperation.[11-14] We used a decision-tree analysis model to 
compare the medium to long-term cost between the two strategies, namely TT alone and TT+pCND 
in a reference population with biopsy-proven cN0 PTC.
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MATERIALS AND METHODS 
Case definition 
A hypothetical cohort of 100,000 non-pregnant female patients aged 50 year-old with an unifocal 
intrathyroidal 1.5cm cN0 PTC in the right thyroid lobe and with no previous thyroidectomy or neck 
irradiation was simulated in the model. 
The model 
A decision tree model using TreeAge Software Pro version 2012 (Treeage Software, Inc., 
Williamstown, MA, US) was constructed to compare the estimated long-term cost between TT 
alone and TT+pCND. Patients were entered into the model after primary operation as the initial 
state, based on the Markov process with 1-year cycle as outlined in Figure 1. Patients underwent 
one of two strategies, namely TT alone or TT+pCND, and were followed up until 70 years old. The 
model included 3 major health states after primary treatment and they were disease-free, 
surveillance with LRR and death. In case of LRR involving either the central, lateral or central and 
lateral compartments, a compartment-oriented reoperation followed by RAI were offered. Patient in 
either two strategies may suffer one of six surgical complications from the primary operation. 
Patients were followed up until stage of death or 70 years old.  
Assumptions 
It was assumed all pCNDs were unilateral only and surgical resection was the only option in 
patients with LRR involving the central, lateral or central and lateral compartments. All patients 
were assumed suitable and agreed for reoperation at the time of LRR. For simplicity, only a 
maximum of one LRR and one reoperation per patient was assumed. Similarly, only one surgical 
complication was encountered after primary operation and reoperation. Reoperative CND was 
assumed bilateral while reoperative lateral SND was assumed unilateral involving levels II-V. An 
empirical 3GBq RAI was given after each reoperation. The costs of preoperative assessment and 
surveillance were assumed the same in both groups. Full compliance was assumed for all kinds of 
assessment, treatment and surveillance. 
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Probabilities 
Estimates of the complications arising from the primary operation, postoperative radioiodine 
ablation (RAI) and central and/or lateral recurrences after primary operation were based a 
comprehensive literature search but were limited to those studies which directly compared surgical 
complications between TT alone and TT+pCND in cN0 PTC. Details of the search had been 
previously described.[11] Estimates of the complications arising from reoperation and death from 
non-thyroid causes were based on separate PubMed literature searches. To come up with an 
estimate for all clinical parameters, base-case values were derived from multiple studies synthesized 
in literature search. We tested the possible range of the lowest and highest values from 
aforementioned studies in the sensitivity analysis. The annual mortality rate of female patients in 
quinqueenial age groups (e.g. 50-54, 55-59, etc) were obtained from the population projection in 
2012.[15]  
Cost data 
This model looked at the financial impact of two strategies from the institutional perspective. The 
cost from the institutional perspective only included the direct costs of the procedure, its associated 
complications, hospitalization. Indirect costs such as loss of productivity and wages were not 
included. The unit cost of all surgical procedures, RAI and complications were based on the 
Hospital Authority (HA) cost published in the 2013 Government Gazette.[16] The Gazette provides 
the official price list of all medical services utilized in healthcare sector. The operation costs 
included preoperative work-up cost, fees for the surgeon, anesthetist and supporting staff, drugs 
related to the operation, operating room, consumables and all other general expenses. Costs related 
to prolonged hospitalization or readmission due to complications or medical co-morbidities were 
not included. Drug costs were retrieved from the drug price enquiry system.[17] Cost data evaluated 
in Hong Kong dollar (HKD) (year 2013 values) were converted to US dollars (USD) at an exchange 
rate of USD 1.0= HKD7.8 and rounded off to the nearest whole USD dollar. Therefore, all 
monetary values were expressed in USD for international comparisons.  
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Base-case analysis 
The 20-year accumulative medical cost accrued per patient for two strategies was calculated. All the 
costs were discounted by an annual rate of 3%, in line with the established guideline for cost-
analysis.[18] The incremental cost difference was defined as the cost of TT+pCND minus the cost 
of TT alone. 
Sensitivity analysis 
Our models performed the one-way (univariate) sensitivity analysis to explore the uncertainty on 
the clinical parameters of complications, RAI ablation, and annualized recurrence rates. Each 
clinical parameter was varied over the lowest and highest possible values suggested in the literature 
search while the value of other clinical parameters remained constant. Since the complication rates 
in primary operation differed, those complication rates from primary operation were assumed the 
same between the two strategies in bivariate sensitivity analysis. We also performed bivariate 
sensitivity analysis on the surgical complications in which we varied the relative differences in rate 
of permanent vocal cord palsy complication between TT+pCND and TT alone, so as to obtain the 
incremental cost equivalence. Threshold analysis was undertaken to capture the threshold clinical 
values at which the costs of TT alone and TT+pCND became equivalent. We expanded 
considerably more on the range of threshold analysis by adopting the theoretical possible range 
from zero to one. 
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RESULTS 
Base-case analysis 
The base-case analysis was based on the previously stated assumptions and used the base-case 
probabilities and costs from Table 1 and 2. The costs accrued per patient in the primary operation 
under the TT alone and TT+pCND strategies were USD 6702.81 and USD 10062.35, respectively 
and the costs accrued per patient in the reoperation under the TT alone and TT+pCND strategies 
were USD 12981.40 and USD 12509.09, respectively. Table 3 shows the results of base-case and 
sensitivity analyses. From the institutional perspective, the 20-year accumulative cost of TT alone 
accrued per patient was USD 19888.36 while the cost of TT+pCND accrued per patient was USD 
22760.86. Therefore, TT alone was the less expensive than TT+pCND to the institution. 
Sensitivity analysis 
The univariate sensitivity analysis was performed by varying key model parameters to verify the 
robustness of model conclusion. No change in the conclusion was seen by varying various key 
parameters including rates of complications, annualized LRR and RAI after primary operation. 
Even when the model was extended to 50 years, TT alone was less expensive than TT+pCND. In 
the bivariate sensitivity analysis, when the total morbidity after the primary operation in TT+pCND 
was assumed to be equal to TT alone, TT+pCND remained more costly than TT alone. When the 
total morbidity of TT+pCND was reduced from 29.96% to 14.94% (i.e. total morbidity of TT 
alone), the incremental cost remained positive (USD 2870.29). In fact, regardless of the actual total 
morbidity rate, so long as the two strategies had similar morbidity, TT+pCND remained more 
expensive than TT alone. 
Table 4 shows the threshold analysis. Of all the clinical key model parameters, only 5 parameters 
could have made the direct medical cost of TT alone ≥ TT+pCND. These 5 parameters were 
permanent vocal cord palsy rate during TT alone, the 3 annualized recurrence rates under the TT 
alone strategy and rate of RAI ablation after TT+pCND. For the first parameter, the rate of 
permanent vocal cord palsy during TT alone had to rise above 59.84% while the rate of permanent 
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vocal cord palsy during TT+pCND remained at 1.22% before TT alone could become more costly 
than TT+pCND. In that scenario, the total morbidity would have to become 73.76% in TT alone 
while TT+pCND remained at 29.96%. Increasing the rates of central, lateral and central and lateral 
recurrence in TT alone also resulted in a decrease in incremental costs. The annualized central 
recurrence rate in TT alone had to rise from 0.63% to 7.34% before TT alone became more 
expensive. Similarly, the annualized lateral and central and lateral recurrence rates in TT alone had 
to rise from 0.38% to 4.54% and 0.56% to 3.71%, respectively before TT alone would become 
more costly than TT+pCND. A decrease in RAI ablation from 76.87% to 1.67% in TT+pCND 
while maintaining the rate of RAI in TT alone at 53.44% also resulted in equivalent direct medical 
costs between the two strategies.  
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DISCUSSION 
To our knowledge, the issue of costs has rarely been discussed in the context of pCND. Our key 
question was whether adding pCND at the time of TT in cN0 PTC would be cost saving in the 
medium to long term. Our initial hypothesis was that although the addition of pCND at the time of 
TT may accrue a higher initial cost, this extra cost may perhaps be recovered by the lower LRR and 
need for reoperation over time.[11-14] Our hypothesis was supported by the fact that the primary 
operation cost accrued per patient in the TT alone was less than TT+pCND (USD 6702.81 and USD 
10062.35, respectively) while the reoperation cost accrued per patient in TT alone was more than 
TT+pCND (USD 12981.40 and USD 12509.09, respectively). However, despite these findings, 
TT+pCND turned out USD 2872.50 more expensive than TT alone over a 20-year period. Even 
when the model was extended to a 50-year period, the TT+pCND remained more expensive by 
USD 2737.52. 
The factors which led to the higher initial cost in TT+pCND included extra cost of pCND, higher 
complication rates from the primary operation and higher frequent of RAI ablation after primary 
operation. Under our service cost structure, pCND cost USD 2494.0 and that accounted for a third 
of the total cost of TT+pCND (USD 7006) or >50% the cost of TT (USD 4512). Also because the 
overall initial complication rate was higher in TT+pCND than TT alone (29.96% vs. 14.94%), the 
initial cost of TT+pCND was higher than TT alone. Regarding RAI ablation, since patients who 
underwent pCND were more likely to be upstaged by metastatic central lymph nodes,[7-9,11,12] 
RAI ablation was given more frequently in the TT+pCND strategy. 
Although the cost accrued per patient in the reoperation setting was higher in the TT alone strategy 
than TT+pCND strategy (i.e. consistent to our initial hypothesis), the actual cost difference over 
time was not enough to compensate for the initial cost difference. The incremental cost difference 
was only USD 472.31 whereas the incremental cost difference in the primary operation setting was 
USD 3359.54. However, this could be explained firstly because under our service cost structure, the 
cost of primary CND and reoperative CND was similar, even though reoperation required greater 
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surgical skills and longer procedural time.[13,14] Secondly, from the literature, the complication 
rates from reoperation were not significantly higher than those from the primary operation. Both 
temporary hypoparathyroidism (20.64% vs. 17.14%) and overall morbidity (29.96% vs. 30.40%) 
rate were not too dissimilar to reoperative CND. The other factor was the low absolute LRR in TT 
alone. Although the LRR in TT alone was higher than that in TT+pCND (1.57% vs. 1.07%), the 
absolute difference was small and that led to smaller incremental cost difference. In fact, based on 
the threshold analysis, the annualized LRR had to increase by > 6–12 times before the cost of the 
two strategies become equivalent at 20 years. Other clinical scenarios were when the permanent 
vocal cord palsy rate in TT alone rose to ≥60% while the rate in TT+pCND remained 1.7% or when 
the use of RAI ablation after TT+pCND was reduced from 76.87% to 1.67%. 
Despite these findings, there were several shortcomings with our model. Firstly, our findings were 
based on our own unique service cost structure and so the actual costs may not be applicable to 
other health systems and countries. Secondly, despite a comprehensive literature search for 
estimating different probabilities, selection and publication biases could not be completely ruled out. 
For example, base-case temporary and permanent vocal cord palsy rates in TT+pCND were not 
significantly higher than the TT alone (3.28% vs. 3.10% and 1.70% vs. 1.22%, respectively). 
Nevertheless, according to the two-way sensitivity analysis, even if TT+pCND had the same overall 
morbidity as TT alone, TT alone remained the less costly strategy. Thirdly, some of the 
assumptions might have been overly simplified. For example, assuming one LRR and one 
reoperation per patient would appear overly-simplified because up to 10% of patients with first-time 
LRR would require more than one reoperations.[14,15] Given the higher LRR rate in the TT alone, 
including ≥2 reoperations could potentially increase the cost accrued in TT alone. In addition, 
although the literature would suggest that RAI is given more often after TT+pCND than TT alone 
because of tumor upstaging,[11,12] there is currently no evidence to suggest that it should. In fact, 
some would argue that if nodal status is unknown (such as those without pCND), RAI should be 
given routinely (i.e. more frequently) to facilitate long-term follow-up.  
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One point worth noting is that this study evaluated only the costs accrued from an institution’s 
perspective and not from the surgeon’s or patient’s perspective. To the surgeon or patient, 
TT+pCND might still be more preferable because overall LRR risk was reduced by almost half 
(from 1.57% to 0.87%). Perhaps, future studies could also study the relative impact of primary 
operation and reoperation on patients’ quality of life. 
 
CONCLUSION 
From an institution’s perspective, the addition of pCND at the time of TT for cN0 PTC was not cost 
saving in the medium to long term. This was partly because of higher initial cost in TT+pCND and 
relatively small difference in LRR between TT alone and TT+pCND. From an institution’s 
perspective, TT alone was a much less costly strategy than TT+pCND. 
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Table 1. Literature-based probabilities 
Clinical Parameters Base case (%) Range for sensitivity 
analysis (%) 
References 
Complications from the primary operation 
- Temporary vocal cord palsy 
  - Total thyroidectomy alone 
  - Total thyroidectomy + prophylactic CND 
- Permanent vocal cord palsy 
  - Total thyroidectomy alone  
  - Total thyroidectomy + prophylactic CND 
- Temporary hypoparathyroidism 
  - Total thyroidectomy alone 
  - Total thyroidectomy + prophylactic CND 
- Permanent hypoparathyroidism 
  - Total thyroidectomy alone  
  - Total thyroidectomy + prophylactic CND 
- Hematoma formation requiring reoperation 
  - Total thyroidectomy alone  
  - Total thyroidectomy + prophylactic CND 
- Wound infection 
  - Total thyroidectomy alone  
  - Total thyroidectomy + prophylactic CND 
- Total morbidity* 
 
 
3.10 
3.28 
 
1.22 
1.70 
 
7.73 
20.64 
 
0.85 
1.47 
 
0.99 
1.79 
 
1.07 
1.16 
 
 
 
0.00 – 6.38 
0.00 – 7.26 
 
0.00 – 2.74 
0.0 – 2.51 
 
4.03 – 33.63 
8.70 – 42.86 
 
0.00 – 8.11 
0.0 – 5.88 
 
0.00 – 3.08 
0.00 – 2.50 
 
0.0 – 1.54 
0.0 – 1.16 
 
 
 
8,9,20-28 
8,9,20-28 
 
8,9,20,22-25,27,28 
8,9,20,22-25,27,28 
 
8,9,20-28 
8,9,20-28 
 
8,9,21-28 
8,9,21-28 
 
8,9,20-22,24,25,27 
8,9,20-22,24,25,27 
 
8,9,20-22,24-26 
8,9,20-22,24-26 
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  - Total thyroidectomy alone 
  - Total thyroidectomy + prophylactic CND 
14.94 
29.96 
 
Complications from reoperative CND 
- Temporary vocal cord palsy 
- Permanent vocal cord palsy 
- Temporary hypoparathyroidism 
- Permanent hypoparathyroidism 
- Hematoma 
- Wound infection 
- Chyle leakage 
- Total morbidity* 
 
4.04 
2.70 
17.14 
1.70 
1.10 
1.92 
1.80 
30.40 
 
1.59 – 22.22 
0.00 – 17.78 
6.06 – 42.22 
0.00 – 5.00 
0.00 – 4.35  
0.00 – 4.35 
0.00 – 2.22 
 
 
29-36 
29-36 
29-36 
29-36 
29,30,31,33,35 
29,30,31,33,35 
29,33,35 
Complications from lateral selective neck dissection 
- Chyle leakage 
 
5.51 
 
5.8 – 5.83 
 
37-39 
Annualized locoregional recurrence rate 
- Central compartment only 
  - Total thyroidectomy alone  
  - Total thyroidectomy + prophylactic CND 
- Lateral compartment only 
  - Total thyroidectomy alone  
  - Total thyroidectomy + prophylactic CND 
- Central and lateral compartments 
  - Total thyroidectomy alone  
  - Total thyroidectomy + prophylactic CND 
 
 
0.63 
0.22 
 
0.38 
0.36 
 
0.56 
0.29 
 
 
0.00 – 1.83 
0.00 – 0.82 
 
0.00 – 3.73 
0.00 – 1.57 
 
0.00 – 1.87 
0.00 – 0.41 
 
 
8,9,20-28 
8,9,20-28 
 
8,9,20-28 
8,9,20-28 
 
8,9,20-28 
8,9,20-28 
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- Overall locoregional recurrence rate  
  - Total thyroidectomy alone 
  - Total thyroidectomy + prophylactic CND 
 
1.57 
0.87 
 
 
Likelihood of RAI after primary operation 
- Total thyroidectomy alone  
- Total thyroidectomy + prophylactic CND 
 
53.44 
76.87 
 
28.01 – 100.00 
58.09 – 100.00 
 
8,9,21,24,25,27,28,40,41 
8,9,21,24,25,27,28,40,41 
Number of deaths per 1000 population 
-50 – 54 
-55 – 59 
-60 – 64 
-65 – 69 
-70 – 74 
-75 – 79 
-80 – 84 
-85+ 
 
1.8 
2.5 
4.0 
6.0 
10.3 
20.0 
37.7 
93.8 
 16 
Abbreviations: CND = central neck dissection; RAI = radioiodine ablation 
* total morbidity was the sum of all complications; patients with more than one complication were counted as one  
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Table 2. Unit cost (USD) for each service component for the care of papillary thyroid carcinoma 
patients 
 Unit cost 
(USD) 
Reference 
Surgical procedure 
- Total thyroidectomy 
- Central neck dissection (initial or reoperative) 
- Lateral selective neck dissection (reoperative) 
 
4512 
2494 
5219 
 
17 
17 
17 
RAI ablation 
- Specialist consult, blood tests (TSH, Tg, Anti-
Tg abs), recombinant TSH injections, RAI (3.3 
Gbq) ablation, hospital stay (2 nights), post-
treatment whole body scan 
3820 
 
17,18 
 
 
Complications from primary operation or 
reoperation 
Temporary vocal cord palsy+ 
 - Otolaryngology consult, laryngoscopy, follow-
up visit, speech therapy 
Permanent vocal cord palsy# 
 - Otolaryngology consult, laryngoscopy, follow-
up visit, speech therapy, vocal cord medialization 
Temporary hypoparathyroidism+ 
 - Follow-up visits, blood tests, medications 
Permanent hypoparathyroidism (annual cost)# 
 - Follow-up visits, blood tests, medications 
Chyle leak* 
Hematoma requiring neck re-exploration 
Wound infection 
 
 
1383 
 
 
4951 
 
 
416 
 
444 
 
4250 
2442 
1300 
 
 
17 
 
 
17 
 
 
17,18 
 
17,18 
 
17 
17 
17 
Routine Surveillance (annual cost) 800 17 
Abbreviations: RAI = radioiodine; TSH = thyroid stimulating hormone; Tg = thyroglobulin; Anti-
Tg abs = anti-thyroglobulin auto-antibodies 
+ assumed an average of 2-month duration 
# includes monthly visit for the first 6 months and then thereafter 6-monthly follow-up  
* assumed to be managed successfully with conservative treatment  
 18 
Table 3. Results of base-case and sensitivity analyses 
 Average direct medical cost (in USD) accrued per 
patient 
Base-case analysis TT alone TT+pCND Incremental 
cost 
 19888.36 22760.86 2872.5 
 
Univariate sensitivity analysis  
Clinical parameters Range for sensitivity 
analysis (%) 
Range for incremental 
cost (USD) per patient 
TT alone 
Complications from primary operation 
- Temporary vocal cord palsy 
- Permanent vocal cord palsy 
- Temporary hypoparathyroidism 
- Permanent hypoparathyroidism 
- Hematoma requiring reoperation 
- Wound infection 
Complications from reoperative CND 
- Temporary vocal cord palsy 
- Permanent vocal cord palsy 
- Temporary hypoparathyroidism 
- Permanent hypoparathyroidism 
- Hematoma requiring reoperation 
- Wound infection 
- Chyle leakage 
Complications from lateral SND 
- Chyle leakage 
Annualized LR recurrence rate 
- Recurrence in central compartment 
- Recurrence in lateral compartment 
- Recurrence in central and lateral 
compartments 
RAI ablation after primary operation 
 
 
0.00 – 6.38 
0.00 – 2.74 
4.03 – 33.63 
0.00 – 8.11 
0.00 – 3.08 
0.00 – 1.54 
 
1.59 – 22.22 
0.00 – 17.78 
6.06 – 42.22 
0.00 – 5.00 
0.00 – 4.35 
0.00 – 4.35 
0.00 – 2.22 
 
5.21 – 5.83 
 
0.00 to 1.83 
0.00 to 3.73 
0.00 to 1.87 
 
28.01 to 100.00 
 
 
2917.87 to 2829.63 
2962.61 to 2826.95 
2887.90 to 2764.76 
2883.03 to 2782.56 
2896.68 to 2821.47 
2886.41 to 2866.39 
 
2877.81 to 2833.15 
2893.43 to 2755.65 
2879.72 to 2856.17 
2883.97 to 2850.24 
2876.71 to 2860.08 
2876.41 to 2867.56 
2884.48 to 2869.71 
 
2873.14 to 2871.82 
 
2066.93 to 3366.04 
3292.55 to 126.10 
3710.80 to 1189.91 
 
3843.93 to 1093.91 
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TT+pCND 
Complications from primary operation 
- Temporary vocal cord palsy 
- Permanent vocal cord palsy 
- Temporary hypoparathyroidism 
- Permanent hypoparathyroidism 
- Hematoma requiring reoperation 
- Wound infection 
Complications from reoperative CND 
- Temporary vocal cord palsy 
- Permanent vocal cord palsy 
- Temporary hypoparathyroidism 
- Permanent hypoparathyroidism 
- Hematoma requiring reoperation 
- Wound infection 
- Chyle leakage 
Complications from lateral SND 
- Chyle leakage 
Annualized LR recurrence rate 
- Recurrence in central compartment 
- Recurrence in lateral compartment 
- Recurrence in central and lateral 
compartments 
RAI ablation after primary operation 
 
 
0.00 – 7.26 
0.00 – 2.51 
8.70 – 42.86 
0.00 – 5.88 
0.00 – 2.50 
0.00 – 1.16 
 
1.59 – 22.22 
0.00 – 17.78 
6.06 – 42.22 
0.00 – 5.00 
0.00 – 4.35 
0.00 – 4.35 
0.00 – 2.22 
 
5.21 – 5.83 
 
0.00 to 0.82 
0.00 to 1.57 
0.00 to 0.41 
 
58.09 to 100.00 
 
 
2856.05 to 2956.45 
2831.91 to 2956.18 
2822.83 to 2964.94 
2857.75 to 2916.75 
2828.79 to 2889.84 
2857.42 to 2872.50 
 
2870.14 to 2890.07 
2863.17 to 2924.65 
2869.28 to 2879.79 
2867.47 to 2882.27 
2870.63 to 2878.05 
2870.76 to 2874.71 
2867.16 to 2873.75 
 
2871.53 to 2873.55 
 
2688.30 to 3341.36 
2189.08 to 3953.84 
2415.96 to 3055.06 
 
2155.11 to 3756.07 
Year cycle 20 to 50 years 2872.50 to 2737.52 
Discount rate 0 to 3 2735.54 to 2872.50 
 
Bivariate sensitivity Analysis Value (%) Incremental cost (USD) 
per patient 
Assuming equivalent total morbidity in 
primary operation between TT alone 
and TT+pCND 
  
- Total Morbidity of TT+pCND 29.96 2868.82 
- Total Morbidity of TT alone 14.94 2870.29 
 20 
- Total Morbidity  0.00 2872.29 
Abbreviations: TT = total thyroidectomy; pCND = prophylactic central neck dissection; SND = 
selective neck dissection; LR = locoregional; RAI = radioiodine  
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Table 4. Threshold analysis of clinical values at which the direct medical costs of total 
thyroidectomy (TT) alone and total thyroidectomy and prophylactic central neck dissection 
(TT+CND) became equivalent over a 20-year period 
Clinical parameters Base-case (%) Threshold (%) Values for  
incremental cost < 0 
TT alone 
- Permanent vocal cord palsy at primary 
operation 
- Annual recurrence in central compartment 
- Annual recurrence in lateral compartment 
- Annual recurrence in central and lateral 
compartments 
 
1.22 
 
0.63 
0.38 
0.56 
 
59.84 
 
7.34 
4.54 
3.71 
 
59.84, 100.00 
 
7.34, 100.00 
4.55, 100.00 
3.71, 100.00 
TT+pCND 
- RAI ablation 
 
76.87 
 
1.67 
 
0.00, 1.67 
Abbreviations: TT = total thyroidectomy; pCND = prophylactic central neck dissection
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LEGENDS 
Figure 1. A simplified tree diagram representing the decision tree model for the comparison of total 
thyroidectomy (TT) without prophylactic central neck dissection (pCND) (TT alone) and TT with 
pCND (TT+pCND) strategies applied in patients with clinically nodal negative papillary thyroid 
carcinoma 
 
